View Financial HealthDecoy Therapeutics 配当と自社株買い配当金 基準チェック /06Decoy Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-598.3%バイバック利回り総株主利回り-598.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jul 27Decoy Therapeutics Demonstrates In Vitro Activity Of D-MAV Candidate Against Wild-Type Ebola Zaire Virus And Opens Exploratory Program To Design D-MAVs Against Filoviruses Including Ebola And MarburgDecoy Therapeutics Inc. announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT platform to block coronavirus entry, where it has shown nanomolar to picomolar activity across known coronavirus strains. Its activity against Ebola Zaire, a filovirus responsible for 17 of the last 20 Ebola outbreaks, demonstrates the value of the platform's founding premise that one drug engineered against common viral machinery can address many viruses and serve many people. In the same testing, the candidate also showed in vitro activity against Lassa fever virus, an arenavirus. Filovirus diseases, including Ebola, Marburg, and Lassa fever are among the conditions eligible for the FDA's tropical disease priority review voucher program, which supports development of treatments for diseases that lack sufficient commercial markets. The D-MAV was engineered against a mechanism coronaviruses depend on, and it inhibited filovirus infection because they rely on the same class I fusion machinery. This activity validates the strategy behind the broad-based antiviral platform, and demonstrates the breadth of D-MAV effectiveness. Decoy Therapeutics is now designing new D-MAVs for multi-viral inhibition of filoviruses and arenaviruses, the development of which the platform can accelerate. Addressing commercial markets and pandemic preparedness through the same work is how the platform is meant to operate. An ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda, caused by Bundibugyo virus and lacking any approved vaccine or treatment, underscores why that reach matters.お知らせ • Jul 15Decoy Therapeutics Inc. Elects Patricia Gauthier as Class II DirectorDecoy Therapeutics Inc. announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held July 14, 2026. Patricia Gauthier has served as Senior Vice President, Regional Head for Australia, Canada and the United Kingdom at Moderna since 2025, leading strategy and operations across biomanufacturing, national health security partnerships and commercialization. She previously served as General Manager of Moderna Canada, where she built the affiliate from inception, supported the delivery of more than 50 million COVID-19 vaccine doses, and helped secure a biomanufacturing partnership with the Government of Canada. She also held senior leadership roles at GSK across vaccines, specialty care, market access and government affairs, and began her career as a lawyer at McCarthy Tétrault.New Risk • Jun 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.5m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 44x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.94m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$12m net loss next year).お知らせ • May 20Decoy Therapeutics Inc., Annual General Meeting, Jul 14, 2026Decoy Therapeutics Inc., Annual General Meeting, Jul 14, 2026.New Risk • May 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.5m free cash flow). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 53x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.04m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$12m net loss next year).New Risk • Apr 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 19% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 53x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.09m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years).New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 61% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.4m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings are forecast to decline by an average of 61% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 65x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.79m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$16m net loss in 2 years).お知らせ • Jan 13Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing PlatformDecoy Therapeutics Inc. announced that the development of a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals is a key 'funded development' of Decoy's Global Access Commitment Agreement (GACA) with the Gates Foundation. Decoy is creating an easily transferable manufacturing capability for peptide-conjugated antivirals designed on its IMP3ACT platform that can rapidly advance therapeutic products from laboratory to commercial scale. Decoy is working with a leading contract manufacturing organization based in the U.S. and Europe to establish the manufacturing capability. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor funded from the same grant, which demonstrates the 'design-for-manufacturing' capability of Decoy's proprietary IMP3ACT platform. The intranasal pan-Coronavirus inhibitor is being developed as a conveniently administered, broad-acting, antiviral to prevent and mitigate infections from multiple coronaviruses in immune-compromised and high-risk populations. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress on other programs including a novel broad-acting antiviral to treat flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. Decoy's drug design engine uses the power of computational tools and fast peptide synthesis technology pioneered in the laboratory of Brad Pentelute, Ph.D., Professor of Chemistry at MIT and Decoy co-founder, to rapidly engineer and synthesize novel antivirals that directly target highly conserved viral machinery. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT platform. Readers areurged to carefully review and consider the various disclosures made by Decoy's Company's proprietary IMP3ACT™? platform.お知らせ • Jan 04Salarius Pharmaceuticals, Inc. Receives Notice of Nasdaq Delisting Due to Non-Compliance with Listing RulesOn December 31, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq listing rule 5810(c)(3)(A)(iv) and the Company remaining subject to a Mandatory Panel Monitor, the Company is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because the Company has effected a reverse stock split during the prior one-year period. Accordingly, unless the Company requests an appeal of the delisting determination by January 7, 2026, Nasdaq has determined that the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on January 9, 2026. In addition, a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company intends to appeal the delisting determination on or before January 7, 2026 by requesting an appeal with a Nasdaq Hearings Panel (the “Hearings Panel”). A request for an appeal will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Hearings Panel’s decision. The Company intends to present its plans to regain compliance with the Minimum Bid Price Requirement. However, there are no assurances a favorable decision from the Hearing Panel will be obtained or that the Company’s securities will remain listed on The Nasdaq Capital Market.決済の安定と成長配当データの取得安定した配当: DCOYの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: DCOYの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Decoy Therapeutics 配当利回り対市場DCOY 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DCOY)n/a市場下位25% (US)1.3%市場トップ25% (US)4.0%業界平均 (Biotechs)2.1%アナリスト予想 (DCOY) (最長3年)n/a注目すべき配当: DCOYは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: DCOYは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: DCOYの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DCOYが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/28 23:02終値2026/07/28 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Decoy Therapeutics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Aydin HuseynovBenchmark CompanyMichael KingH.C. Wainwright & Co.
お知らせ • Jul 27Decoy Therapeutics Demonstrates In Vitro Activity Of D-MAV Candidate Against Wild-Type Ebola Zaire Virus And Opens Exploratory Program To Design D-MAVs Against Filoviruses Including Ebola And MarburgDecoy Therapeutics Inc. announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg. The candidate was engineered on Decoy's IMP3ACT platform to block coronavirus entry, where it has shown nanomolar to picomolar activity across known coronavirus strains. Its activity against Ebola Zaire, a filovirus responsible for 17 of the last 20 Ebola outbreaks, demonstrates the value of the platform's founding premise that one drug engineered against common viral machinery can address many viruses and serve many people. In the same testing, the candidate also showed in vitro activity against Lassa fever virus, an arenavirus. Filovirus diseases, including Ebola, Marburg, and Lassa fever are among the conditions eligible for the FDA's tropical disease priority review voucher program, which supports development of treatments for diseases that lack sufficient commercial markets. The D-MAV was engineered against a mechanism coronaviruses depend on, and it inhibited filovirus infection because they rely on the same class I fusion machinery. This activity validates the strategy behind the broad-based antiviral platform, and demonstrates the breadth of D-MAV effectiveness. Decoy Therapeutics is now designing new D-MAVs for multi-viral inhibition of filoviruses and arenaviruses, the development of which the platform can accelerate. Addressing commercial markets and pandemic preparedness through the same work is how the platform is meant to operate. An ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda, caused by Bundibugyo virus and lacking any approved vaccine or treatment, underscores why that reach matters.
お知らせ • Jul 15Decoy Therapeutics Inc. Elects Patricia Gauthier as Class II DirectorDecoy Therapeutics Inc. announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held July 14, 2026. Patricia Gauthier has served as Senior Vice President, Regional Head for Australia, Canada and the United Kingdom at Moderna since 2025, leading strategy and operations across biomanufacturing, national health security partnerships and commercialization. She previously served as General Manager of Moderna Canada, where she built the affiliate from inception, supported the delivery of more than 50 million COVID-19 vaccine doses, and helped secure a biomanufacturing partnership with the Government of Canada. She also held senior leadership roles at GSK across vaccines, specialty care, market access and government affairs, and began her career as a lawyer at McCarthy Tétrault.
New Risk • Jun 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 25% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.5m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 44x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$2.94m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$12m net loss next year).
お知らせ • May 20Decoy Therapeutics Inc., Annual General Meeting, Jul 14, 2026Decoy Therapeutics Inc., Annual General Meeting, Jul 14, 2026.
New Risk • May 11New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$6.5m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$6.5m free cash flow). Earnings are forecast to decline by an average of 21% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 53x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.04m market cap). Minor Risk Currently unprofitable and not forecast to become profitable next year (US$12m net loss next year).
New Risk • Apr 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 19% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 53x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$3.09m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$18m net loss in 2 years).
New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 61% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$4.4m free cash flow). Share price has been highly volatile over the past 3 months (30% average weekly change). Earnings are forecast to decline by an average of 61% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 65x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$4.79m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$16m net loss in 2 years).
お知らせ • Jan 13Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing PlatformDecoy Therapeutics Inc. announced that the development of a flexible, globally accessible manufacturing platform for peptide-conjugate antivirals is a key 'funded development' of Decoy's Global Access Commitment Agreement (GACA) with the Gates Foundation. Decoy is creating an easily transferable manufacturing capability for peptide-conjugated antivirals designed on its IMP3ACT platform that can rapidly advance therapeutic products from laboratory to commercial scale. Decoy is working with a leading contract manufacturing organization based in the U.S. and Europe to establish the manufacturing capability. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor funded from the same grant, which demonstrates the 'design-for-manufacturing' capability of Decoy's proprietary IMP3ACT platform. The intranasal pan-Coronavirus inhibitor is being developed as a conveniently administered, broad-acting, antiviral to prevent and mitigate infections from multiple coronaviruses in immune-compromised and high-risk populations. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress on other programs including a novel broad-acting antiviral to treat flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. Decoy's drug design engine uses the power of computational tools and fast peptide synthesis technology pioneered in the laboratory of Brad Pentelute, Ph.D., Professor of Chemistry at MIT and Decoy co-founder, to rapidly engineer and synthesize novel antivirals that directly target highly conserved viral machinery. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on their business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP3ACT platform. Readers areurged to carefully review and consider the various disclosures made by Decoy's Company's proprietary IMP3ACT™? platform.
お知らせ • Jan 04Salarius Pharmaceuticals, Inc. Receives Notice of Nasdaq Delisting Due to Non-Compliance with Listing RulesOn December 31, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq listing rule 5810(c)(3)(A)(iv) and the Company remaining subject to a Mandatory Panel Monitor, the Company is not eligible for any compliance period specified in Nasdaq listing rule 5810(c)(3)(A) because the Company has effected a reverse stock split during the prior one-year period. Accordingly, unless the Company requests an appeal of the delisting determination by January 7, 2026, Nasdaq has determined that the Company’s securities will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on January 9, 2026. In addition, a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. The Company intends to appeal the delisting determination on or before January 7, 2026 by requesting an appeal with a Nasdaq Hearings Panel (the “Hearings Panel”). A request for an appeal will stay the suspension of the Company’s securities and the filing of the Form 25-NSE pending the Hearings Panel’s decision. The Company intends to present its plans to regain compliance with the Minimum Bid Price Requirement. However, there are no assurances a favorable decision from the Hearing Panel will be obtained or that the Company’s securities will remain listed on The Nasdaq Capital Market.